Literature DB >> 23408632

RNA helicase signaling is critical for type i interferon production and protection against Rift Valley fever virus during mucosal challenge.

Megan E Ermler1, Ekaterina Yerukhim, Jill Schriewer, Stefan Schattgen, Zachary Traylor, Adam R Wespiser, Daniel R Caffrey, Zhijian J Chen, Charles H King, Michael Gale, Marco Colonna, Katherine A Fitzgerald, R Mark L Buller, Amy G Hise.   

Abstract

Rift Valley fever virus (RVFV) is an emerging RNA virus with devastating economic and social consequences. Clinically, RVFV induces a gamut of symptoms ranging from febrile illness to retinitis, hepatic necrosis, hemorrhagic fever, and death. It is known that type I interferon (IFN) responses can be protective against severe pathology; however, it is unknown which innate immune receptor pathways are crucial for mounting this response. Using both in vitro assays and in vivo mucosal mouse challenge, we demonstrate here that RNA helicases are critical for IFN production by immune cells and that signaling through the helicase adaptor molecule MAVS (mitochondrial antiviral signaling) is protective against mortality and more subtle pathology during RVFV infection. In addition, we demonstrate that Toll-like-receptor-mediated signaling is not involved in IFN production, further emphasizing the importance of the RNA cellular helicases in type I IFN responses to RVFV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23408632      PMCID: PMC3624317          DOI: 10.1128/JVI.01997-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

Review 1.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

Review 2.  Exotic emerging viral diseases: progress and challenges.

Authors:  Thomas W Geisbert; Peter B Jahrling
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

Review 3.  Toll-like receptor and RIG-I-like receptor signaling.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

4.  The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses.

Authors:  Vijay A K Rathinam; Zhaozhao Jiang; Stephen N Waggoner; Shruti Sharma; Leah E Cole; Lisa Waggoner; Sivapriya Kailasan Vanaja; Brian G Monks; Sandhya Ganesan; Eicke Latz; Veit Hornung; Stefanie N Vogel; Eva Szomolanyi-Tsuda; Katherine A Fitzgerald
Journal:  Nat Immunol       Date:  2010-03-28       Impact factor: 25.606

5.  Mycobacterium bovis BCG decreases MHC-II expression in vivo on murine lung macrophages and dendritic cells during aerosol infection.

Authors:  Nicole D Pecora; Scott A Fulton; Scott M Reba; Michael G Drage; Daimon P Simmons; Nancy J Urankar-Nagy; W Henry Boom; Clifford V Harding
Journal:  Cell Immunol       Date:  2008-08-30       Impact factor: 4.868

6.  Activation of MDA5 requires higher-order RNA structures generated during virus infection.

Authors:  Andreas Pichlmair; Oliver Schulz; Choon-Ping Tan; Jan Rehwinkel; Hiroki Kato; Osamu Takeuchi; Shizuo Akira; Michael Way; Giampietro Schiavo; Caetano Reis e Sousa
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

7.  RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection.

Authors:  A M A Nasirudeen; Hui Hui Wong; Peiling Thien; Shengli Xu; Kong-Peng Lam; Ding Xiang Liu
Journal:  PLoS Negl Trop Dis       Date:  2011-01-04

8.  Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction.

Authors:  Matthias Habjan; Ida Andersson; Jonas Klingström; Michael Schümann; Arnold Martin; Petra Zimmermann; Valentina Wagner; Andreas Pichlmair; Urs Schneider; Elke Mühlberger; Ali Mirazimi; Friedemann Weber
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

9.  Inflammasome recognition of influenza virus is essential for adaptive immune responses.

Authors:  Takeshi Ichinohe; Heung Kyu Lee; Yasunori Ogura; Richard Flavell; Akiko Iwasaki
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

10.  Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.

Authors:  Tetsuro Ikegami; Krishna Narayanan; Sungyong Won; Wataru Kamitani; C J Peters; Shinji Makino
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823

View more
  16 in total

1.  RIG-I-dependent antiviral immunity is effective against an RNA virus encoding a potent suppressor of RNAi.

Authors:  Xiaoxu Fan; Shuwei Dong; Yang Li; Shou-wei Ding; Ming Wang
Journal:  Biochem Biophys Res Commun       Date:  2015-04-03       Impact factor: 3.575

2.  Rift Valley fever virus infection induces activation of the NLRP3 inflammasome.

Authors:  Megan E Ermler; Zachary Traylor; Krupen Patel; Stefan A Schattgen; Sivapriya K Vanaja; Katherine A Fitzgerald; Amy G Hise
Journal:  Virology       Date:  2013-12-03       Impact factor: 3.616

3.  Activation of the chicken type I interferon response by infectious bronchitis coronavirus.

Authors:  Joeri Kint; Marcela Fernandez-Gutierrez; Helena J Maier; Paul Britton; Martijn A Langereis; Joseph Koumans; Geert F Wiegertjes; Maria Forlenza
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

4.  Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

Authors:  N Oreshkova; L Spel; R P M Vloet; P J Wichgers Schreur; R J M Moormann; M Boes; J Kortekaas
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

5.  Interplay between the Virus and Host in Rift Valley Fever Pathogenesis.

Authors:  Kaori Terasaki; Shinji Makino
Journal:  J Innate Immun       Date:  2015-02-27       Impact factor: 7.349

6.  Antiviral autophagy restrictsRift Valley fever virus infection and is conserved from flies to mammals.

Authors:  Ryan H Moy; Beth Gold; Jerome M Molleston; Veronica Schad; Kilangsungla Yanger; Mary-Virginia Salzano; Yoshimasa Yagi; Katherine A Fitzgerald; Ben Z Stanger; Samantha S Soldan; Sara Cherry
Journal:  Immunity       Date:  2013-12-26       Impact factor: 31.745

7.  Association of symptoms and severity of rift valley fever with genetic polymorphisms in human innate immune pathways.

Authors:  Amy G Hise; Zachary Traylor; Noémi B Hall; Laura J Sutherland; Saidi Dahir; Megan E Ermler; Samuel Muiruri; Eric M Muchiri; James W Kazura; A Desirée LaBeaud; Charles H King; Catherine M Stein
Journal:  PLoS Negl Trop Dis       Date:  2015-03-10

8.  Development of a novel, single-cycle replicable rift valley Fever vaccine.

Authors:  Shin Murakami; Kaori Terasaki; Sydney I Ramirez; John C Morrill; Shinji Makino
Journal:  PLoS Negl Trop Dis       Date:  2014-03-20

9.  Nonspreading Rift Valley Fever Virus Infection of Human Dendritic Cells Results in Downregulation of CD83 and Full Maturation of Bystander Cells.

Authors:  Nadia Oreshkova; Paul J Wichgers Schreur; Lotte Spel; Rianka P M Vloet; Rob J M Moormann; Marianne Boes; Jeroen Kortekaas
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240

Review 10.  Phleboviruses and the Type I Interferon Response.

Authors:  Jennifer Deborah Wuerth; Friedemann Weber
Journal:  Viruses       Date:  2016-06-22       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.